tried to get as far away from Type 1 diabetes as possible — literally and figuratively.
"Ultimately, I got really angry and the switch flipped. If I was born there, I would be dead. That really hit close to home," she said."I took stock of my career and threw myself into the diabetes space." It is an advance, backed recently by a grant from California regenerative medicine funding agency CIRM, that could personalize and simplify care. Now Digovich and her team are trying to bring it home.A lot of the work we've done to date has been with research-grade cell lines, and with CIRM, we are going to be doing this work with a clinically relevant cell line.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: